Promising Results for Viking Weight-Loss Drug

by Warren Seah

Viking Therapeutics Inc.’s stock VKTX soared 61% early Tuesday, following the announcement of positive results from a Phase 2 trial of its weight-loss drug VK2735. This drug, a GLP-1 receptor agonist, is being developed in both injectable and oral form to address obesity and diabetes.

Successful Trial Outcomes

The trial successfully met all primary and secondary endpoints, demonstrating statistically significant reductions in body weight across all doses in comparison to the placebo group. After 13 weeks, patients receiving weekly doses of VK2735 lost up to an impressive 14.7% of their body weight from the baseline.

Impressive Statistics

According to the company’s statement, up to 88% of patients in the VK2735 treatment groups achieved a weight loss of >=10%, a stark contrast to the 4% observed in the placebo group.

Moving Forward

Viking plans to engage with the Food and Drug Administration for discussions on the next steps post these compelling trial results. With the stock having surged by 250% in the last year, compared to a 27% increase in the S&P 500, positive momentum surrounds Viking Therapeutics Inc.’s groundbreaking development in the realm of weight-loss solutions.

You may also like

Leave a Comment